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evaluate whether the value of SUVmax and RI can diagnose as lung 
cancer or the presence of lymph node metastasis.
Results: Eighty-one patients were diagnosed as lung cancer and the 
median SUVmax was 9.2 (range, 0.8 to 24). Ten patients were diag-
nosed as benign nodules and the median SUVmax was 3.1 (range, 1.6 
to 8.9). There was a signiﬁcant difference of SUVmax between lung 
cancer and benign tumor (p<0.001). The correlation between tumor 
size in lung cancer and SUVmax were recognized (r=0.67). If the cut-
off value of SUVmax was 3.5 or greater to depict malignant tumors, the 
sensitivity and speciﬁcity in all pulmonary nodules were 84% and 80%. 
The sensitivity and speciﬁcity in tumors more than 3cm in diameter 
were 98% and 100%. On the other hand, in tumors less than 3cm in 
diameter, the sensitivity and speciﬁcity were 48% and 86%. However, 
if the tumor with either RI of more than 10% or SUVmax of more than 
3.5 is classiﬁed as lung cancer, the sensitivity and speciﬁcity was 83% 
and 86% in tumors less than 3cm in diameter. Four hundred and sixty 
lymph nodes of the hilum and the mediastinum were dissected. Twenty-
one of those were metastatic lymph nodes (4.6%). If the lymph nodes 
with 1cm or greater in minor diameter at the chest CT scan are judged 
with metastasis, the sensitivity, speciﬁcity and accuracy were 50%, 
97% and 33%, respectively. Whereas if the cut-off value of SUVmax 
is 3.5 or greater to depict lymph node metastasis at FDG-PET/CT, the 
sensitivity, speciﬁcity and accuracy were 80%, 99% and 76%, respec-
tively. There were 14 false-positive lymph nodes at the chest CT scan 
and 5 false-positive ones at FDG-PET/CT. 
Conclusion: In the tumors more than 3 cm in diameter, the value of 
SUVmax was a very useful tool for diagnosis of lung cancer. However, 
in the tumors less than 3 cm in diameter, the value of RI in addition to 
SUVmax was useful for diagnosis. FDG-PET/CT was signiﬁcantly bet-
ter than the chest CT scan for diagnosis of lymph node metastasis. 
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Background: This systematic review evaluates the accuracy and utility 
of 18Fluorodeoxyglucose positron emission tomography in the diagno-
sis and staging of both non-small cell and small cell lung cancer.
Methods: Relevant health technology assessments, randomized trials 
and meta-analyses were identiﬁed through a systematic search of the 
literature. The Lung Disease Site Group (LDSG) has used the prac-
tice guideline (PG) development cycle described by Browman GP 
et al (JCO 1998; 16(3):1226-31). A unique aspect of the PG is that it 
incorporates practitioner feedback to evaluate the acceptance of the 
guideline among its practitioners.
Results: One high-quality health technology assessment developed by 
the Institute for Clinical and Evaluative Sciences (ICES) in Ontario 
from 2001 was retrieved and formed the basis for this expanded sys-
tematic review. Twelve additional evidence summary reports, including 
meta-analyses, were reviewed. Thirteen additional prospective studies 
of the diagnostic accuracy of PET and three randomized controlled tri-
als evaluating the utility of PET in staging and diagnosis were retrieved 
in a search of the primary literature published following or beyond 
the scope of the ICES report. PET has high sensitivity, and reasonable 
speciﬁcity for differentiating benign from malignant lesions as small 
as 1 cm in size. PET is superior to CT imaging for mediastinal staging 
in NSCLC. PET has not been studied as extensively in patients with 
SCLC, but the available data shows good accuracy in staging extensive 
versus limited disease. Randomized trials reporting on the utility of 
PET report conﬂicting results in terms of the relative reduction in futile 
thoracotomies. Many studies have evaluated the accuracy of 18FDG-
PET in the diagnosis and staging of lung cancer; however there is 
limited evidence to determine the impact of PET on clinically impor-
tant patient outcomes. 
Practitioner feedback was obtained through a series of mail out ques-
tionnaires to stakeholders that included surgical, medical and radiation 
oncologists as well as nuclear medicine physicians. The itemized ques-
tionnaire elicited feedback regarding the rationale for the guideline, 
completeness of the literature search, and acceptance of the methodol-
ogy and recommendations. The percentage of responses that agreed or 
strongly agreed were 80% (rationale for the guideline), 76% (complete-
ness of literature search), 81% (acceptance of methodology), 56% 
(agree with draft recommendations) and 49% (approve as a guideline).
Conclusion: PET has high sensitivity and reasonable speciﬁcity in 
differentiating benign from malignant processes in lung cancer. PET 
may improve results of early-stage lung cancer by excluding patients 
who have evidence of metastatic disease which is beyond the scope of 
surgical resection and is not evident by standard preoperative staging 
procedures. While the systematic review is regarded as a complete and 
thorough summary of the literature, practitioners disagree on the inter-
pretation of the literature and the clinical utility of PET in the manage-
ment of lung cancer.
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Background: This systematic review evaluates the available evidence 
on the role of Positron Emission Tomography (PET) and Co-registered 
Computed Tomography (CT) simulation in radiation treatment planning 
for lung cancer.
Methods: Relevant studies that incorporated PET or gamma cam-
era coincidence imaging (GCCI) into radiation treatment planning 
were identiﬁed through a systematic search of the published clinical 
literature using major electronic indexes (e.g., MEDLINE, EMBASE, 
COCHRANE). 
Results: Twenty-one studies incorporating PET (n=18) or GCCI (n=3) 
into the radiation treatment planning process for patients with lung can-
cer were identiﬁed from 1996 to 2006. Resolution capabilities of PET 
